Evaluation of the association of anticholinergic burden and delirium in older hospitalised patients - A cohort study comparing 19 anticholinergic burden scales.


Journal

British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323

Informations de publication

Date de publication:
11 2022
Historique:
revised: 16 05 2022
received: 19 05 2021
accepted: 19 05 2022
pubmed: 9 6 2022
medline: 14 10 2022
entrez: 8 6 2022
Statut: ppublish

Résumé

A recent review identified 19 anticholinergic burden scales (ABSs) but no study has yet compared the impact of all 19 ABSs on delirium. We evaluated whether a high anticholinergic burden as classified by each ABS is associated with incident delirium. We performed a retrospective cohort study in a Swiss tertiary teaching hospital using data from 2015-2018. Included were patients aged ≥65, hospitalised ≥48 hours with no stay >24 hours in intensive care. Delirium was defined twofold: (i) ICD-10 or CAM and (ii) ICD-10 or CAM or DOSS. Patients' cumulative anticholinergic burden score, calculated within 24 hours after admission, was classified using a binary (<3: low, ≥3: high burden) and a categorical approach (0: no, 0.5-3: low, ≥3: high burden). Association was analysed using multivariable logistic regression. Over 25 000 patients (mean age 77.9 ± 7.6 years) were included. Of these, (i) 864 (3.3%) and (ii) 2770 (11.0%) developed delirium. Depending on the evaluated ABS, 4-63% of the patients were exposed to at least one anticholinergic drug. Out of 19 ABSs, (i) 14 and (ii) 16 showed a significant association with the outcomes. A patient with a high anticholinergic burden score had odds ratios (ORs) of 1.21 (95% confidence interval [CI]: 1.03-1.42) to 2.63 (95% CI: 2.28-3.03) for incident delirium compared to those with low or no burden. A high anticholinergic burden within 24 hours after admission was significantly associated with incident delirium. Although prospective studies need to confirm these results, discontinuing or substituting drugs with a score of ≥3 at admission might be a targeted intervention to reduce incident delirium.

Identifiants

pubmed: 35675080
doi: 10.1111/bcp.15432
pmc: PMC9796852
doi:

Substances chimiques

Cholinergic Antagonists 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4915-4927

Informations de copyright

© 2022 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

Références

Biochem Med (Zagreb). 2012;22(3):276-82
pubmed: 23092060
Arch Intern Med. 2008 Mar 10;168(5):508-13
pubmed: 18332297
J Neurol Neurosurg Psychiatry. 2010 Feb;81(2):160-5
pubmed: 19770163
Drugs Aging. 2021 Mar;38(3):233-242
pubmed: 33415708
Dig Dis Sci. 2022 Aug;67(8):3938-3947
pubmed: 34365536
J Am Med Dir Assoc. 2014;15(11):825-9
pubmed: 25282629
J Am Med Dir Assoc. 2020 Apr;21(4):481-485
pubmed: 31983551
J Am Geriatr Soc. 2008 Dec;56(12):2203-10
pubmed: 19093918
Crit Care Med. 2015 Sep;43(9):1846-52
pubmed: 26010688
Int J Geriatr Psychiatry. 2018 Nov;33(11):1428-1457
pubmed: 29278283
Int J Geriatr Psychiatry. 2017 Jun;32(6):650-656
pubmed: 27280553
Geriatr Gerontol Int. 2019 Jul;19(7):628-634
pubmed: 31033150
Clin Pharmacol Ther. 2008 Jul;84(1):63-8
pubmed: 17987049
Nat Rev Neurol. 2009 Apr;5(4):210-20
pubmed: 19347026
Neuropsychiatr Dis Treat. 2013;9:1359-70
pubmed: 24092976
Ther Adv Drug Saf. 2017 Nov;8(11):361-370
pubmed: 29090085
J Am Geriatr Soc. 2021 Feb;69(2):547-555
pubmed: 33135780
BMC Geriatr. 2018 Oct 11;18(1):239
pubmed: 30305048
Am J Psychiatry. 2004 Jan;161(1):116-24
pubmed: 14702259
J Clin Pharmacol. 2006 Dec;46(12):1481-6
pubmed: 17101747
Basic Clin Pharmacol Toxicol. 2022 Feb;130(2):288-300
pubmed: 34837340
Comput Inform Nurs. 2018 Nov;36(11):515-520
pubmed: 30399004
J Am Geriatr Soc. 2009 Aug;57(8):1354-61
pubmed: 19573218
J Crit Care. 2017 Dec;42:268-274
pubmed: 28806561
Br J Pharmacol. 2006 Jul;148(5):565-78
pubmed: 16751797
Can J Psychiatry. 2003 Sep;48(8):555-60
pubmed: 14574831
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
N Engl J Med. 2017 May 25;376(21):2004-2006
pubmed: 28538132
Jpn J Nurs Sci. 2018 Oct;15(4):298-308
pubmed: 29266727
Einstein (Sao Paulo). 2019 Apr 01;17(2):eAO4435
pubmed: 30942279
Basic Clin Pharmacol Toxicol. 2019 Jun;124(6):741-748
pubmed: 30511428
Eur J Clin Pharmacol. 2013 Jul;69(7):1485-96
pubmed: 23529548
BMJ. 2007 Apr 21;334(7598):842-6
pubmed: 17446616
J Gerontol A Biol Sci Med Sci. 2008 Jul;63(7):764-72
pubmed: 18693233
Intensive Crit Care Nurs. 2018 Feb;44:99-104
pubmed: 29054400
PLoS One. 2016 Mar 03;11(3):e0150621
pubmed: 26939130
Clin Nurs Res. 2021 May;30(4):464-473
pubmed: 33174438
J Am Geriatr Soc. 2011 Nov;59 Suppl 2:S277-81
pubmed: 22091573
Eur J Clin Pharmacol. 2021 Feb;77(2):147-162
pubmed: 33011824
J Clin Nurs. 2019 Jul;28(13-14):2537-2542
pubmed: 30786081
Arch Intern Med. 2001 Apr 23;161(8):1099-105
pubmed: 11322844
Life Sci. 1978 May 1;22(17):1511-6
pubmed: 672410
Basic Clin Pharmacol Toxicol. 2014 Feb;114(2):151-9
pubmed: 24112192
Palliat Med. 2014 Apr;28(4):335-41
pubmed: 24534725
J Am Geriatr Soc. 2008 Jul;56(7):1333-41
pubmed: 18510583
Therapie. 2017 Sep;72(4):427-437
pubmed: 28336159
Pharmacol Res Perspect. 2017 May 11;5(3):e00310
pubmed: 28603629
Br J Clin Pharmacol. 2022 Nov;88(11):4915-4927
pubmed: 35675080
Eur J Intern Med. 2020 Aug;78:121-126
pubmed: 32487370
Respiration. 2020;99(8):637-645
pubmed: 32634800
BMJ. 2006 Feb 25;332(7539):455-9
pubmed: 16452102
J Am Geriatr Soc. 2011 Aug;59(8):1477-83
pubmed: 21707557
Dement Geriatr Cogn Disord. 2011;31(3):173-8
pubmed: 21389718

Auteurs

Angela Lisibach (A)

Clinical Pharmacy, Department Medical Services, Cantonal Hospital of Baden, Baden, Switzerland.
Center for Research and Innovation in Clinical Pharmaceutical Sciences, University Hospital and University of Lausanne, Lausanne, Switzerland.
School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Switzerland.

Giulia Gallucci (G)

Clinical Pharmacy, Department Medical Services, Cantonal Hospital of Baden, Baden, Switzerland.

Valérie Benelli (V)

Clinical Pharmacy, Department Medical Services, Cantonal Hospital of Baden, Baden, Switzerland.

Ramona Kälin (R)

Clinical Pharmacy, Department Medical Services, Cantonal Hospital of Baden, Baden, Switzerland.

Sven Schulthess (S)

Clinical Pharmacy, Department Medical Services, Cantonal Hospital of Baden, Baden, Switzerland.

Patrick E Beeler (PE)

Division of Occupational and Environmental Medicine, Epidemiology, Biostatistics and Prevention Institute, University of Zurich & University Hospital Zurich, Zurich, Switzerland.

Chantal Csajka (C)

Center for Research and Innovation in Clinical Pharmaceutical Sciences, University Hospital and University of Lausanne, Lausanne, Switzerland.
School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Switzerland.

Monika Lutters (M)

Clinical Pharmacy, Department Medical Services, Cantonal Hospital of Baden, Baden, Switzerland.
Swiss Federal Institute of Technology, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH